NCT01885949 2026-02-24
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
Clinical Trials
4 trialsNCT01297244 2020-10-27
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 2 Completed
NCT01673386 2020-10-27
TAURUS
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00502307 2020-09-01
A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 2 Completed